miRNA-944和miRNA-3662的血浆循环前体在非小细胞肺癌检测中的诊断作用。

The diagnostic role of plasma circulating precursors of miRNA-944 and miRNA-3662 for non-small cell lung cancer detection.

作者信息

Powrózek Tomasz, Kuźnar-Kamińska Barbara, Dziedzic Marcin, Mlak Radosław, Batura-Gabryel Halina, Sagan Dariusz, Krawczyk Paweł, Milanowski Janusz, Małecka-Massalska Teresa

机构信息

Department of Human Physiology, Medical University of Lublin, Poland.

Department of Pulmunology, Allergology and Respiratory Oncology, Poznań University of Medical Sciences, Poland.

出版信息

Pathol Res Pract. 2017 Nov;213(11):1384-1387. doi: 10.1016/j.prp.2017.09.011. Epub 2017 Sep 18.

DOI:10.1016/j.prp.2017.09.011

PMID:28964576

Abstract

INTRODUCTION

microRNA (miRNA) seem to be most attractive cancer markers due their crucial role in tumor development and possibility of their analysis using liquid biopsy. To date there is little known about role of miRNA precursors (pri-miRNA) in carcinogenesis and their utility as tumor markers.

MATERIAL AND METHODS

miRNA-944 and miRNA-3662 precursors as potential non-small cell lung cancer (NSCLC) markers were analyzed in plasma samples of 56 patients in an early stage of NSCLC and 100 healthy individuals.

RESULTS

Diagnostic test based on two studied markers for stage I-IIIA of the disease allowed to distinguish NSCLC from healthy individuals with 75.7% sensitivity and 82.3% specificity (AUC=0.898). pri-miRNA-944 distinguished SCC from AC with sensitivity of 78.6% and specificity of 91.7% (AUC=0.771), and pri-miRNA-3662 distinguished AC from SCC with 57.1% sensitivity and 90% specificity (AUC=0.845).

CONCLUSION

Circulating pri-miRNA-944 and 3662 can improve non-invasive NSCLC detection of operable stages of SCC and AC. miRNA precursors could be considered as novel potential lung cancer biomarkers.

摘要

引言

微小RNA（miRNA）似乎是极具吸引力的癌症标志物，因为它们在肿瘤发展中起着关键作用，并且可以通过液体活检进行分析。迄今为止，关于miRNA前体（pri-miRNA）在致癌作用中的作用及其作为肿瘤标志物的效用知之甚少。

材料与方法

在56例非小细胞肺癌（NSCLC）早期患者和100名健康个体的血浆样本中，分析了miRNA-944和miRNA-3662前体作为潜在的NSCLC标志物。

结果

基于两种研究标志物对疾病I-IIIA期进行的诊断测试，能够以75.7%的灵敏度和82.3%的特异性将NSCLC与健康个体区分开来（曲线下面积[AUC]=0.898）。pri-miRNA-944区分鳞状细胞癌（SCC）和腺癌（AC）的灵敏度为78.6%，特异性为91.7%（AUC=0.771），而pri-miRNA-3662区分AC和SCC的灵敏度为57.1%，特异性为90%（AUC=0.845）。